Basildon / Cambridge (UK), 27 January 2020 – Atnahs, a Triton Fund V portfolio company, has signed an agreement to acquire the global (ex-China, India, Japan and US) commercial rights to a portfolio of Cardiovascular medicines used primarily to treat hypertension – namely, Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination) from AstraZeneca.
Founded in 2013, Atnahs has significantly increased its product portfolio since inception through its strong relationships with leading pharma companies. The acquisition is a further step for Atnahs to deliver medicines that patients, prescribers, healthcare systems and regulators value as well as building out its Cardiovascular product portfolio. It also underlines the company’s strong track record of being a preferred acquirer for large cap or specialty pharma businesses choosing to divest their established brands.
“ The acquisition is strategically important and strengthens our position in Cardiovascular medicine. We consider these established medicines as highly trusted by patients and prescribers alike, and as very stable globally. The acquisition of these high-quality brands increases our size and diversification significantly ”, says Dr. Amit Patel, CEO of Atnahs.
Atnahs is a specialty pharmaceutical business, focused on acquiring mature branded medicines out of large cap and specialty pharma companies globally and developing its own niche medicines. Atnahs operates a portfolio of 20 brands with over 1,800 SKUs across more than 140 markets, with a focus on therapeutic areas such as Women’s Health, Pain, Oncology and Cardiovascular.
For further information: www.atnahs.com
Since its establishment in 1997, Triton has sponsored nine funds, focusing on businesses in the industrial, business services, consumer and healthcare sectors. The Triton funds invest in and support the positive development of medium-sized businesses headquartered in Europe.
Triton seeks to contribute to the building of better businesses for the longer term. Triton and its executives wish to be agents of positive change towards sustainable operational improvements and growth.
The 41 companies currently in Triton’s portfolio have combined sales of around €16.5 billion and around 80,000 employees.
For further information: www.triton-partners.com
Phone: +49 69 9210 2190